Metformin and Berberine Prevent Olanzapine-Induced Weight Gain in Rats
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Olanzapine is a first line medication for the treatment of schizophrenia, but it is also one of the atypical antipsychotics carrying the highest risk of weight gain. Metformin was reported to produce significant attenuation of antipsychotic-induced weight gain in patients, while the study of preventing olanzapine-induced weight gain in an animal model is absent. Berberine, an herbal alkaloid, was shown in our previous studies to prevent fat accumulation in vitro and in vivo. Utilizing a well-replicated rat model of olanzapine-induced weight gain, here we demonstrated that two weeks of metformin or berberine treatment significantly prevented the olanzapine-induced weight gain and white fat accumulation. Neither metformin nor berberine treatment demonstrated a significant inhibition of olanzapine-increased food intake. But interestingly, a significant loss of brown adipose tissue caused by olanzapine treatment was prevented by the addition of metformin or berberine. Our gene expression analysis also demonstrated that the weight gain prevention efficacy of metformin or berberine treatment was associated with changes in the expression of multiple key genes controlling energy expenditure. This study not only demonstrates a significant preventive efficacy of metformin and berberine treatment on olanzapine-induced weight gain in rats, but also suggests a potential mechanism of action for preventing olanzapine-reduced energy expenditure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome
Wajchenberg, B. L. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.6.0415 · Cited by 2,961
Cellular and molecular mechanisms of metformin: an overview
Viollet, B., Guigas, B., Garcia, N. S., Leclerc, J., Foretz, M., & Andreelli, F. (2012) · Clinical Science · doi:10.1042/cs20110386 · Cited by 1,720
Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.
De Hert, M., Detraux, J., van Winkel, R., Yu, W., & Correll, C. U. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.156 · Cited by 1,145
Miyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001556 · Cited by 988 · cited 1×
“Second generation antipsychotics [1] are the first line medications for acute and maintenance therapy of schizophrenia, due to fewer neurological side effects and arguably greater improvement in negative symptoms, when compared with first generation antipsychotics [2,3].”
BackgroundZhang, X., Zhao, Y., Zhang, M., Pang, X., Xu, J., Kang, C., Li, M., Zhang, C., Zhang, Z., Zhang, Y., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042529 · Cited by 615 · cited 1×
“In the last decade, emerging evidence demonstrated that berberine treatment can induce weight loss in rodents [29,30] and human subjects [31,32].”
BackgroundTreatment of Type 2 Diabetes and Dyslipidemia with the Natural Plant Alkaloid Berberine
Zhang, Y., Li, X., Zou, D., Liu, W., Yang, J., Zhu, N., Huo, L., Wang, M., Hong, J., Wu, P., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2404 · Cited by 573 · cited 1×
“In the last decade, emerging evidence demonstrated that berberine treatment can induce weight loss in rodents [29,30] and human subjects [31,32].”
BackgroundThe metabolic effects of antipsychotic medications
Newcomer, J. W., & Haupt, D. W. (2006) · The Canadian Journal of Psychiatry · doi:10.1177/070674370605100803 · Cited by 315 · cited 1×
“The prevalence of metabolic syndrome after second generation antipsychotic treatment was reported to be 20–60%, which is at least double the prevalence rate in the general population [11–17].”
BackgroundLee, M.-S., Kim, I.-H., Kim, C.-T., & Kim, Y. (2011) · The Journal of Nutrition · doi:10.3945/jn.111.146050 · Cited by 100
Kreuzer, P., Landgrebe, M., Wittmann, M., Schecklmann, M., Poeppl, T. B., Hajak, G., & Langguth, B. (2012) · The Journal of Clinical Pharmacology · doi:10.1177/0091270011409233 · Cited by 53
Cited by
Berberis Vulgaris and Berberine: An Update Review
Imenshahidi, M., & Hosseinzadeh, H. (2016) · Phytotherapy Research · doi:10.1002/ptr.5693 · Cited by 359
Tokubuchi, I., Tajiri, Y., Iwata, S., Hara, K., Wada, N., Hashinaga, T., Nakayama, H., Mifune, H., & Yamada, K. (2017) · PLOS ONE · doi:10.1371/journal.pone.0171293 · Cited by 121
Och, A., Och, M., Nowak, R., Podgórska, D., & Podgórski, R. (2022) · Molecules · doi:10.3390/molecules27041351 · Cited by 104
Effects of lisdexamfetamine in a rat model of binge-eating
Vickers, S. P., Hackett, D., Murray, F., Hutson, P. H., & Heal, D. J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115615107 · Cited by 56
Verhaegen, A. A., & Van Gaal, L. F. (2021) · Current Obesity Reports · doi:10.1007/s13679-020-00419-5 · Cited by 53
“induced by olanzapine and was associated with favorable changes in the expression of several genes controlling energy expenditure [63].”
Background
Metadata
- Authors
- Hu, Y., Young, A. J., Ehli, E. A., Nowotny, D., Davies, P. S., Droke, E. A., Soundy, T. J., & Davies, G. E.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-03-25
- Volume
- 9
- Issue
- 3
- Pages
- e93310
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2077542376
- Cited by
- 76
- References
- 9
- FWCI
- 3.68
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.